Saturday, 6 Sep 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Ryan Group of Schools’ INMUN 2025: Young Leaders Unite to Shape the Future
    Ryan Group of Schools’ INMUN 2025: Young Leaders Unite to Shape the Future
    06/09/2025
    Patrick Hemingway, American Writer, Wildlife Conservationist and Last Surviving Son of Nobel Prize Winner, Ernest Hemingway, 97, has passed
    Patrick Hemingway, American Writer, Wildlife Conservationist and Last Surviving Son of Nobel Prize Winner, Ernest Hemingway, 97, has passed
    06/09/2025
    StarCharge Signs Landmark 1GWh BESS Solution Agreement with India’s Leading EPC and IPP Prozeal Green Energy
    StarCharge Signs Landmark 1GWh BESS Solution Agreement with India’s Leading EPC and IPP Prozeal Green Energy
    05/09/2025
    Nexteer Signs Agreement for New Smart Manufacturing Project in Suzhou, China
    Nexteer Signs Agreement for New Smart Manufacturing Project in Suzhou, China
    05/09/2025
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    ADFW 2025: World’s Financial Elite Managing Over USD 60 Trillion to Explore How Technology is Shaping Finance
    05/09/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • global
  • Business
  • july
  • announced
  • today
  • aug
  • company
  •  and
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure

PRNW Agency
Last updated: 27/07/2025 6:19 AM
PRNW Agency
Share
5 Min Read
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
SHARE
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure

ZUG, Switzerland, July 23, 2025 /PRNewswire/ — Berlin Heals and the C-MIC II Investigators today announced the publication of the C-MIC II trial results in the European Journal of Heart Failure. The study, titled “Cardio-microcurrent Device Treatment for Heart Failure with Reduced Ejection Fraction: Results from the C-MIC II Open Label Randomized Controlled Trial,” was previously presented as a Late-Breaking Clinical Trial (LBCT) at the 2025 ESC-HFA Congress in Belgrade.

- Advertisement -

 

- Advertisement -

The findings mark a major advancement in the field of bioelectronic medicine for heart failure, highlighting the potential of the Cardio-Microcurrent (C-MIC) device—a novel implantable system that delivers low-intensity microcurrent to the failing myocardium.

Study Summary

- Advertisement -

In this open-label, randomized controlled trial, 70 ambulatory patients with non-ischemic dilated cardiomyopathy, LVEF 25–35%, and NYHA Class III–IV symptoms were randomized 1:1 to receive C-MIC therapy plus guideline-directed medical therapy (GDMT) or GDMT alone. The primary endpoint was the difference in change in LVEF at 6 months. Secondary endpoints included change in NYHA class, 6-minute walk distance (6MWD), and Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS).

- Advertisement -

At six months, patients receiving C-MIC therapy experienced markedly greater improvements than controls across all prespecified endpoints. Left-ventricular ejection fraction (LVEF) rose by an average of 6.6% in the C-MIC group versus 1.5% in the control group, yielding a mean between-group difference of 5.1% (95 % CI 3.1–7.1; p < 0.001). Clinically meaningful functional gains were similarly superior: 84 % of C-MIC patients improved by at least one NYHA class compared with 15 % of controls—a risk difference of 68.9 % (95 % CI 50.6–87.2; p < 0.001). Quality-of-life also benefited, with 75 % of C-MIC patients achieving a ≥5-point increase in KCCQ Overall Summary Score versus 15 % in controls (risk difference 60.0 %, 95 % CI 42.3–77.6; p < 0.001). Finally, nearly half of treated patients (47 %) attained at least a 30 % rise in six-minute-walk distance compared with only 9 % of controls (risk difference 38.3 %, 95 % CI 14.4–62.2; p = 0.002), underscoring consistent benefit across structural, symptomatic, and functional outcomes. The therapy was well tolerated, with no device-related serious adverse events reported.

Author and Investigator Quotes

- Advertisement -

“This study offers compelling evidence that microcurrent therapy can enhance both cardiac function and patient-centered outcomes in individuals with HFrEF,” said Prof. Jesus E. Rame, co-first author, The Louis R. Dinon MD Professor of Medicine and Surgery and Enterprise Chief of Advanced Cardiac and Pulmonary Vascular Disease at Thomas Jefferson University. “These findings introduce a promising new therapeutic avenue for patients who remain symptomatic despite receiving optimal medical therapy.” Dr. Rame further noted, “This randomized controlled trial not only demonstrates the efficacy and safety of the therapy in patients with stable, chronic ambulatory heart failure, but also pioneers an entirely novel treatment paradigm aimed at restoring cardiac function in non-ischemic cardiomyopathy.”

- Advertisement -

“This was a remarkable collaborative effort across all participating sites,” said Prof. Dragana N. Kosevic, co-first author and co-Principal Investigator at Dedinje Cardiovascular Institute, Belgrade. “We observed meaningful improvements in symptoms and functional capacity among our patients—an encouraging sign for broader clinical adoption.”

Prof. Jan Schmitto, Professor of Cardiac Surgery at the Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, co-first author and coordinating investigator of the trial, commented: “These results validate more than a decade of translational work. They suggest that restoring myocardial bioelectric signaling can have a direct and clinically meaningful impact on cardiac performance in patients with advanced heart failure.”

- Advertisement -

Prof. Stefan D. Anker, senior author and Professor of Cardiology at Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin added: “This is the first randomized trial to demonstrate that low-level microcurrent stimulation can improve both structural heart function and quality of life. It establishes a strong foundation for future studies focused on long-term clinical outcomes.”

- Advertisement -

“We are thrilled to see the C-MIC II results published in the European Journal of Heart Failure,” said John Brumfield, CEO of Berlin Heals “These findings support our mission to develop breakthrough, bioelectronic therapies for chronic heart failure—targeting the disease at its electrical and cellular roots.”

To access the full publication in European Journal of Heart Failure, please visit https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3763

- Advertisement -

Disclaimer:

- Advertisement -

The C-MIC device is investigational and not approved for commercial use in any jurisdiction. Its safety and effectiveness are still under evaluation.

Logo – https://mma.prnewswire.com/media/2622179/5421325/Berlin_Heals_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/landmark-trial-demonstrates-efficacy-of-microcurrent-therapy-in-heart-failure-c-mic-ii-results-published-in-the-european-journal-of-heart-failure-302510850.html

- Advertisement -
Ares Management Acquires Minority Stake in Plenitude for 2 Billion
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
Beijing Hosts Inauguration of ICTO, Uniting 50 Global Leaders to Advance CCUS Innovation
Cyber A.I. Group and Synergy Associates Form Strategic Joint Venture to Beta Test CyberAI Sentinel 2.0 Platform
InspireMD Announces CE Mark Approval for CGuard Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
TAGGED: theannouncedberlinc-miccmiccontrolleddemonstratesdeviceefficacyejectioneuropeanfailurefractionhealsheartinvestigatorsjournaljulylabellandmarkmicrocurrentnewsopenpreviouslypublicationpublishedrandomizedreducedresultsstudyswitzerlandthe cmicthe europeantherapytitled cardiomicrocurrenttodaytreatmenttrialtrial resultszug
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

ShareChat & Moj Announce Second Edition of ‘Short Form Big Impact Leadership Summit 2025’
Entertainment

ShareChat & Moj Announce Second Edition of ‘Short Form Big Impact Leadership Summit 2025’

02/08/2025
GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch
Health

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

02/07/2025
Hafnia Limited Announces Financial Results For The Three and Six Months Ended 30 June 2025
Business

Hafnia Limited Announces Financial Results For The Three and Six Months Ended 30 June 2025

27/08/2025
adidas premieres new episode of docuseries featuring Ballon d’Or winner Aitana Bonmat told by her best friend Maria Rodriguez
Sports

adidas premieres new episode of docuseries featuring Ballon d’Or winner Aitana Bonmat told by her best friend Maria Rodriguez

16/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?